Explore seven biotech companies advancing clinical drugs in the race for regulatory approval to revolutionize hepatitis B ...

Gain valuable insights into novel therapies, ongoing clinical trials, and future innovations shaping the treatment of ...

Kurnool: With a spike in hepatitis B and hepatitis C virus cases, the Clinical Microbiology wing at Nandyal Government ...

The Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE-HBV, an investigational gene editing therapy for adults with chronic hepatitis B.

Chronic HBV was associated with increased risk for adverse COVID-19 outcomes, but the risk was lower among coinfected patients vaccinated against COVID-19.

The company is dedicated to educating patients, providers, and others on new findings in chronic hepatitis B virus (HBV) infection. Chronic HBV infection is the most common viral infection in ...

Liver cancer, particularly hepatocellular carcinoma (HCC), has become a major health concern in Uganda. The Uganda Cancer ...

An in-depth look at Hepatitis D, why it’s so severe, and how new therapies bring hope for better treatment and prevention.

According to WHO, 254 million people globally were estimated to have HBV in 2022, but only approximately 10% had been ...

Chronic hepatitis B (CHB) is a long-term infection of the liver caused by the hepatitis B virus (HBV). While acute hepatitis B infection is often resolved by the immune system, CHB occurs when the ...

In April 2025, Vir Biotechnology Inc. announced a phase 1b/2 platform study framework to evaluate the safety and efficacy of ...

This is DTIL’s lead, fully owned in vivo gene editing program aimed at curing chronic hepatitis B by eliminating cccDNA — the primary source of replicating hepatitis B virus (HBV ...